Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Studie av Palifosfamide-tris i kombinasjon med karboplatin og etoposid i kjemoterapi-naive pasienter med småcellet lungekreft i omfattende stadium (MATISSE-studien)

29. september 2026 oppdatert av: Alaunos Therapeutics

En multisenter, åpen etikett, adaptiv, randomisert studie av Palifosfamide-tris, en ny DNA-kryssbinder, i kombinasjon med karboplatin og etoposid (PaCE) kjemoterapi versus karboplatin og etoposid (CE) alene i kjemoterapi-naive pasienter med små, omfattende stadier Celle lungekreft. MATISSE-studien

This is a multinational, multicenter, randomized controlled, open-label, adaptive study to evaluate the efficacy of palifosfamide-tris, carboplatin and etoposide (PaCE) chemotherapy in chemotherapy-naive subjects with extensive-stage small cell lung cancer (SCLC). Eligible subjects will be stratified according to age, gender, and Eastern Cooperative Oncology Group (ECOG) performance status, and randomized in a 1:1 ratio to receive either PaCE or carboplatin and etoposide (CE) chemotherapy.

The study design uses an adaptive group sequential approach with sample size re-estimation at the interim analysis.

Secondary efficacy endpoints include objective response rate (ORR), progression-free survival (PFS), duration of response and changes in quality of life (QOL) and disease-related symptoms. Tumor-related endpoints will be assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guidelines.

The safety of study treatments will be assessed by the frequency and severity of adverse events as determined by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03. To provide an initial confirmation of safety, an early interim analysis of safety data only will be performed.

An independent Data Monitoring Committee (DMC) will be convened to assess the safety and efficacy of the study interventions and to monitor the overall conduct of the clinical trial.

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

188

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • New South Wales
      • Wollongong, New South Wales, Australia, 2500
        • Southern Medical Day Oncology Care Centre
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3E 0V9
        • CancerCare Manitoba
    • Ontario
      • Oshawa, Ontario, Canada, L1G 2B9
        • R. S. McLaughlin Durham Regional Cancer Center at Lakeridge Health Oshawa
    • Quebec
      • Sainte-Foy, Quebec, Canada, G1V 4G5
        • Hôpital Laval
    • Alabama
      • Birmingham, Alabama, Forente stater, 35205
        • Birmingham Hematology and Oncology Associates, LLC
    • California
      • Los Angeles, California, Forente stater, 90033
        • University of Southern California
      • Santa Rosa, California, Forente stater, 95403
        • Redwood Regional Oncology Group
    • Delaware
      • Newark, Delaware, Forente stater, 19713
        • Christiana Care Health Services
    • Florida
      • Jacksonville, Florida, Forente stater, 32207
        • Baptist Cancer Institute
      • Port Saint Lucie, Florida, Forente stater, 34952
        • Hematology Oncology Associates of the Treasure Coast
    • Georgia
      • Atlanta, Georgia, Forente stater, 30318
        • Peachtree Hematology Oncology Consultants
    • Illinois
      • Chicago, Illinois, Forente stater, 60612
        • Rush University Medical Center
      • Galesburg, Illinois, Forente stater, 61401
        • Medical and Surgical Specialists, LLC
      • Niles, Illinois, Forente stater, 60714-5905
        • Illinois Cancer Specialists
    • Indiana
      • Fishers, Indiana, Forente stater, 46037
        • Central Indiana Cancer Centers
      • Goshen, Indiana, Forente stater, 46526
        • Goshen Center for Cancer Care
      • Indianapolis, Indiana, Forente stater, 46202
        • Indiana University
      • Lafayette, Indiana, Forente stater, 47905
        • Horizon Oncology Center
      • Muncie, Indiana, Forente stater, 47303
        • Indiana University Health Ball Memorial Hospital
    • Kansas
      • Overland Park, Kansas, Forente stater, 66210
        • University of Kansas Hospital
    • Kentucky
      • Lexington, Kentucky, Forente stater, 40503
        • Central Baptist Hospital
    • Louisiana
      • Baton Rouge, Louisiana, Forente stater, 70809
        • Medical Oncology, LLC
    • Maryland
      • Frederick, Maryland, Forente stater, 21701
        • Frederick Memorial Hospital Regional Cancer Therapy Center
    • Michigan
      • Wyoming, Michigan, Forente stater, 49519
        • Metro Health Cancer Center
    • Minnesota
      • Duluth, Minnesota, Forente stater, 55805
        • Saint Mary's Medical Center
      • Minneapolis, Minnesota, Forente stater, 55407
        • Virginia Piper Cancer Institute
    • New Jersey
      • Hackensack, New Jersey, Forente stater, 07601
        • John Theurer Cancer Center at Hackensack University Medical Center
      • Morristown, New Jersey, Forente stater, 07962
        • Hematology Oncology Associates of Northern New Jersey, PA, Carol G. Simon Cancer Center
    • New Mexico
      • Albuquerque, New Mexico, Forente stater, 87106
        • University of New Mexico Cancer Center
    • New York
      • Albany, New York, Forente stater, 12110-2188
        • New York Oncology Hematology, PC
      • The Bronx, New York, Forente stater, 10461
        • Montefiore Medical Center
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45219
        • The Christ Hospital
      • Dayton, Ohio, Forente stater, 45429
        • Dayton Cancer Center, Medical Oncology Hematology Associates
    • Pennsylvania
      • Kingston, Pennsylvania, Forente stater, 18704
        • Medical Oncology Associates Of Wyoming Valley, PC
    • South Carolina
      • Charleston, South Carolina, Forente stater, 29403
        • Charleston Hematology Oncology Associates, PA
    • Texas
      • Dallas, Texas, Forente stater, 75230-6899
        • Texas Oncology-Medical City Dallas
      • Dallas, Texas, Forente stater, 75246
        • Texas Oncology- Baylor, Charles A. Sammons Cancer Center
      • Galveston, Texas, Forente stater, 77555-0565
        • University of Texas Medical Branch at Galveston
      • Houston, Texas, Forente stater, 77024
        • Oncology Consultants, PA
      • Wichita Falls, Texas, Forente stater, 76310-1610
        • Texas Oncology, PA
    • Vermont
      • Burlington, Vermont, Forente stater, 05405
        • Fletcher Allen Health Care
    • Virginia
      • Fairfax, Virginia, Forente stater, 22031
        • Fairfax Northern Virginia Hematology-Oncology, PC
    • Washington
      • Seattle, Washington, Forente stater, 98104
        • Swedish Medical Center
    • Wisconsin
      • Madison, Wisconsin, Forente stater, 53705
        • Wisconsin Institutes for Medical Research
      • Strasbourg, Frankrike, 67085
        • Centre Paul Strauss
    • Auvergne-Rhône-Alpes
      • Pierre Bénité, Auvergne-Rhône-Alpes, Frankrike, 69495
        • Centre Hospitalier Lyon Sud
    • Basse-normandie
      • Caen, Basse-normandie, Frankrike, 14076
        • Centre François Baclesse
    • Brittany Region
      • Brest, Brittany Region, Frankrike, 29200
        • Centre Hospitalier Universitaire -Hôpital Morvan
    • Centre-Val de Loire
      • Tours, Centre-Val de Loire, Frankrike, 97044
        • Centre Hospitalier Universitaire, Hopital Bretonneau
    • Limousin, Lorraine
      • Limoges, Limousin, Lorraine, Frankrike, 87042
        • Hôpital du Cluzeau
    • Pays de la Loire Region
      • Saint-Herblain, Pays de la Loire Region, Frankrike, 44805
        • Institut de Cancérologie de l'Ouest - René Gauducheau
    • Provence-Alpes-Côte d'Azur Region
      • Marseille, Provence-Alpes-Côte d'Azur Region, Frankrike, 13008
        • Hôpital Saint Joseph
      • Haifa, Israel
        • Rambam Medical Center
      • Jerusalem, Israel, 91120
        • Hadassah Medical Organization, Ein Kerem
      • Kfar Saba, Israel
        • Meir Hospital Sapir Medical Center
      • Nahariya, Israel, 22100
        • Western Gallilee Medical Center
      • Petah Tikva, Israel, 49100
        • Rabin Medical Center Beilinson Campus
      • Genova, Italia
        • Istituto Nazionale per la Ricerca sul Cancro
      • Milan, Italia, 20162
        • Azienda Ospedaliera Ospedale Niguarda Ca' Granda
      • Trento, Italia, 38100
        • Presidio Ospedaliero S. Chiara
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polen
        • Centrum Onkologii - Instytut im. M. Sklodowskiej-Curie w Warszawie
    • Pomeranian Voivodeship
      • Gdansk, Pomeranian Voivodeship, Polen
        • Uniwersyteckie Centrum Kliniczne
      • Gdansk, Pomeranian Voivodeship, Polen
        • Wojewódzkie Centrum Onkologii
    • West Pomeranian Voivodeship
      • Szczecin, West Pomeranian Voivodeship, Polen
        • Specjalistyczny Szpital im. Alfreda Sokolowskiego
      • Chelaybinsk, Russland, 454087
        • State Budget Institution of Healthcare "Chelyabinsk Regional Clinical Oncology Dispensary"
      • Ivanovo, Russland
        • Ivanovo Regional Oncology Centre
      • Moscow, Russland
        • Cancer Research Center n.a. N.N. Blokhin
      • Nizhny Novgorod, Russland, 603081
        • GUZ of Nizhegorodskiy region, Nizhnij Novgorod City Oncology Dispensary
      • Saint Petersburg, Russland, 194044
        • State Educational Institution "S.M. Kirov Military Medical Academy of Ministry of Defense of Russia"
      • Saint Petersburg, Russland
        • Saint-Petersburg State Medical University n. a. I. P. Pavlov
      • Yaroslavl, Russland, 150040
        • State healthcare institution of Yaroslavl region "Regional Clinical Oncologic Hospital"
    • Bashkortostan Republic
      • Ufa, Bashkortostan Republic, Russland, 450054
        • Republic Clinical Oncology Dispensary of the Ministry of Healthcare of Republic of Bashkortostan
    • Moscow
      • Moscow Region, Moscow, Russland, 143423
        • City Oncology Hospital # 62
    • Primorskiy (Maritime) Kray
      • Arkhangelsk, Primorskiy (Maritime) Kray, Russland, 163045
        • State Institution of Healthcare "Arkhangelsk Regional Clinical Oncology Dispensary"
    • Tatarstan Republic
      • Kazan', Tatarstan Republic, Russland
        • Republican Clinical Oncologic Dispensary of Ministry of health of Republic Tatarstan
    • England
      • Manchester, England, Storbritannia, M23 9LT
        • Wythenshawe Hospital
      • Taichung, Taiwan, 40447
        • China Medical University Hospital
    • Hajdú-Bihar
      • Debrecen, Hajdú-Bihar, Ungarn
        • Debreceni Egyetem Orvos és Egészségtudományi Centrum
    • Heves County
      • Mátraháza, Heves County, Ungarn
        • Mátrai Gyógyintézet

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Documented extensive-stage small cell lung cancer.
  • Patient has received no prior chemotherapy, adjuvant therapy, or radiotherapy for lung cancer.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
  • Adequate bone marrow and organ function based on the results of protocol- specified laboratory tests.
  • Male and female patients must agree to use a highly reliable method of birth control during study participation.
  • Able to provide informed consent

Exclusion Criteria:

  • Previously untreated (non-irradiated), symptomatic brain metastases.
  • Known allergy to any of the study drugs or their excipients.
  • Any unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a patient and/or their compliance with the protocol, based on screening tests, physical examination and medical history (as specifically defined in the clinical protocol).
  • Any malignancy other than small cell lung cancer within the last 5 years prior to randomization, with the exception of cervical carcinoma in situ, nonmelanoma skin cancer, or superficial bladder tumors (Ta, Tis, or T1) that have been successfully and curatively treated with no evidence of recurrent or residual disease. (Exception: Subjects with a history of malignancy other than small cell lung cancer may be enrolled after consultation with the medical monitor provided the patient's prognosis is best defined by the extensive-stage small cell lung cancer).
  • Currently pregnant or nursing.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Palifosfamide-tris plus Carboplatin and Etoposide

Drug: palifosfamide-tris in combination with carboplatin and etoposide palifosfamide-tris: 130 mg/m2/day 3 days every 21 days for a max of 6 cycles. carboplatin: AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a max of 6 cycles.

AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles.

130 mg/m2/day 3 days every 21 days for a max of 6 cycles.

100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.

AUC 5 mg/mL/min 1 day every 21 days for a max of 6 cycles.

Aktiv komparator: Carboplatin plus Etoposide

Drug: carboplatin in combination with etoposide carboplatin: AUC 5mg/mL/min 1 day every 21 days for a maximum of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.

AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles.

100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.

AUC 5 mg/mL/min 1 day every 21 days for a max of 6 cycles.

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Total overlevelse (OS)
Tidsramme: Vurderes hver 12. uke for overlevelse inntil 1 år etter fullført påmelding
Vurderes hver 12. uke for overlevelse inntil 1 år etter fullført påmelding

Sekundære resultatmål

Resultatmål
Tidsramme
Progresjonsfri overlevelse (PFS)
Tidsramme: Vurderes hver 6. uke i 22 uker, deretter hver 12. uke frem til progredierende sykdom, initiering av alternativ kreftbehandling eller 1 år etter den siste pasienten som ble registrert (avhengig av hva som er raskest)
Vurderes hver 6. uke i 22 uker, deretter hver 12. uke frem til progredierende sykdom, initiering av alternativ kreftbehandling eller 1 år etter den siste pasienten som ble registrert (avhengig av hva som er raskest)
Objektiv responsrate (ORR)
Tidsramme: Vurderes hver 6. uke i 22 uker, deretter hver 12. uke til en delvis eller fullstendig respons er bekreftet
Vurderes hver 6. uke i 22 uker, deretter hver 12. uke til en delvis eller fullstendig respons er bekreftet
Svarvarighet
Tidsramme: Tid fra datoen for første objektive respons (delvis eller fullstendig respons), med påfølgende bekreftelse, til datoen for sykdomsprogresjon eller forekomsten av døden
Tid fra datoen for første objektive respons (delvis eller fullstendig respons), med påfølgende bekreftelse, til datoen for sykdomsprogresjon eller forekomsten av døden
Quality of Life (QOL) as Assessed by the EuroQol 5-Dimension 3-Level Questionnaire (EQ-5D-3L) and the European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Module (QLQ-LC13)
Tidsramme: Assessed every 3 weeks for 22 weeks, then every 12 weeks until 1 year following the last patient enrolled
Assessed every 3 weeks for 22 weeks, then every 12 weeks until 1 year following the last patient enrolled
Safety Parameters (Adverse Events and Number of Findings: Physical Examinations, Electrocardiograms [ECGs], Vital Signs, and Clinical Laboratory Results) Using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) 4.03
Tidsramme: 22 weeks
22 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

8. juni 2012

Primær fullføring (Faktiske)

2. desember 2014

Studiet fullført (Faktiske)

2. desember 2014

Datoer for studieregistrering

Først innsendt

12. mars 2012

Først innsendt som oppfylte QC-kriteriene

13. mars 2012

Først lagt ut (Antatt)

15. mars 2012

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

1. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

29. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere